Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
EMD Serono Research & Development Institute, Inc.
With
Merck KGaA, Darmstadt, Germany
Age
0–18
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female subjects 0 to less than 18 years of age at the time of first treatment dose with histologically or cytologically confirmed solid malignant tumors (including CNS tumors) or lymphoma for which no standard therapy is available
Confirmed progression on or refractory to standard therapy or no standard therapy available.
Availability of archival formalin-fixed, paraffin-embedded block containing tumor tissue, or slides, or a fresh/recent tumor biopsy prior to avelumab treatment for subjects in Phase 2
Adequate bone marrow, kidney, and liver function
You may not be if
Prior therapy with any antibody or drug targeting T-cell coregulatory proteins
Concurrent anticancer treatment or immunosuppressive agents
Prior organ transplantation
Significant acute or chronic infections
Other significant diseases or conditions that might impair the subject's tolerance of trial treatment